Canaccord analyst David Hynes lowered the firm’s price target on Definitive Healthcare (DH) to $4 from $5 and keeps a Hold rating on the shares. The firm said the positive takeaways here are that new customer acquisition exceeded internal expectations, the firm is making progress on mitigating downsell pressures, and gross revenue retention should be up year-over-year.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DH:
- Definitive Healthcare Earnings Call: Mixed Sentiment Amid Challenges
- Definitive Healthcare Corp: Solid Q3 Results Amidst Retention Challenges Justify Hold Rating
- Definitive Healthcare price target lowered to $5 from $6 at Stifel
- Definitive Healthcare price target lowered to $3 from $4 at Baird
- Definitive Healthcare Corp. Reports Q3 2025 Results